MODERN APPROACHES TO TREATMENT OF ANXIETY DISORDERS IN ELDERLY PATIENTS
https://doi.org/10.21518/2079-701X-2017-0-60-64
Abstract
Anxiety disorders, along with asthenic, depressive and hypochondriac ones are often observed in elderly patients in general practice. It is believed that about a third of neurological patients suffer from anxiety. Anxiety disorder is revealed in more than 65% of patients with chronic cerebrovascular insufficiency. In these patients a predominance of somatic symptoms over the mental ones is observed, which may lead to difficulties of differential diagnosis of anxiety and somatic pathology. Anxiety leads to a further reduction of patient’s quality of life, disruption of social activity. In this category of patients the risk of development of some somatic diseases, complicated course and worse prognosis of the existing disease are developed. Depression and anxiety are very often comorbid conditions. Buspirone is one of the drugs of choice for treatment of anxiety disorders in the elderly and patients with concomitant somatic pathology.
About the Authors
A. N. Bogolepova
Pirogov Russian National Research Medical University, Moscow
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
E. A. Kovalenko
Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
E. V. Makhnovich
Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
References
1. Kessler RC, Berglund P, Demler O et al Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiat, 2005, 62: 593-602.
2. Вельтищев Д.Ю., Марченко А.С. Генерализованное тревожное расстройство: проблемы диагностики, прогноза и психофармакотерапии. Современная терапия психических расстройств, 2013, 1: 29-35.
3. Петрова Е.А., Савина М.А., Концевой В.А., Скворцова В.И. Клинические особенности постинсультных тревожных расстройств. Журнал неврологии и психиатрии им. С.С. Корсакова, 2012, 112(9): 12-16.
4. Смирнова М.Ю. Депрессивные расстройства у больных дисциркуляторной энцефалопатией. Канд. дисс. М., 2012.
5. Подрезова Л.А., Маркина Т.Р., Сейку Ю.В. Психические нарушения у пожилых терапевтических больных. Альманах клинической медицины, 2014, 35: 89-93.
6. Пресс-выпуск ВЦИОМ №1346, http://wciom. ru/index.php?id=236&uid=12642.
7. Старостина Е.Г. Генерализованное тревожное расстройство и симптомы тревоги в общемедицинской практике. РМЖ, 2004, 12(22): 2-7.
8. Harter MC, Conway KP, Merikangas KR. Associations between anxiety disorders and medical illness. Eur Arch Psychiatry Clin Neurosci, 2003, 253: 313-320.
9. Табеева Г.Р., Азимова Ю.Э. Цереброваскулярные расстройства в пожилом возрасте. Практическая медицина, 2010, 1: 1-56.
10. http://www.who.int/mediacentre/news/releases/2016/depression-anxiety-treatment/en/
11. Yonkers KA, Dyck IR, Warshaw MG, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Brit J Psychiatr, 2000, 176: 544-549.
12. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalized anxiety disorder: systematic review and meta-analysis. BMJ, 2011, 342: 433-437.
13. Fulton В, Brogden RN. Buspilone an updated review of its clinical рhаrmаcology and theгa-peutic applications. CNS Drugs, 1997, 7(1): 68-88.
14. Jacobson АF, Dominguez RA, Goldstein BJ, Steinbook RM. Соmраrisоп of Buspirone and Diazepam in Generalized Anxiety Disorder. Рhаrmасоtherapy, l985, 5(5): 290-296.
15. Cohn JB, Rickels K. A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Curr. Med. Res. Opin., 1989, 11: 304-320.
16. Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety – a pooled, multistudy, double-blind evaluation of bus-pirone. Neuropsychobiology, 1990, 21: 124-130.
17. Delle Chiaie R, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini M. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. Journal of Clinical Psychopharmacology, 1995, 15(1): 12-19.
18. Chessick CA, AllenMH, ThaseME, Batista Miralha da Cunha AABC, Kapczinski FFK, Silva de LimaM, dos Santos Souza JJSS. Azapirones for general-ized anxiety disorder. Cochrane Database of Systematic Reviews, 2006, Issue 3. Art. No.: CD006115. DOI: 10.1002/14651858.CD006115.
19. Norden MJ. Buspirone treatment of sexual dysfuntion associated with selective serotonin re-uptake inhibitors. Depression, 1994, 2: 109-112.
20. Landen M, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology, 1999, 19(3): 268-271.
21. Дамулин И.В., Суворова И.А. Современная концепция повышения эффективности терапии антидепрессантами. Журнал неврологии и психиатрии им. С.С. Корсакова, 2015, 3: 106-112.
22. Mokhber N, Azarpazhooh MR, Khajehdaluee M, Velayati A, Hopwood M. Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatry and Clinical Neurosciences, 2010, 64: 128-133.
23. Ritchie LD, Cox J. A multicentre study of bus pirone in the treatment of anxiety disorders in the elderly. Br J Clin Res, 1993, 4: 131-9.
24. Robinson D, Napoliello MJ, Schenk J. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients. Clin Ther, 1988, 10(6): 740-6.
Review
For citations:
Bogolepova AN, Kovalenko EA, Makhnovich EV. MODERN APPROACHES TO TREATMENT OF ANXIETY DISORDERS IN ELDERLY PATIENTS. Meditsinskiy sovet = Medical Council. 2017;(1S):60-64. (In Russ.) https://doi.org/10.21518/2079-701X-2017-0-60-64
Views:
1150
Email this article 